Altimmune Q3 revenue beats expectations

Altimmune

06/11/2025 12:11

Overview

Altimmune Q3 revenue and net income beat analyst expectations

Adjusted EPS for Q3 beats consensus, reflecting improved financial performance

Company strengthens executive team with key appointments

Outlook

Altimmune expects 48-week data from Phase 2b IMPACT trial in Q4 2025

Company to hold End-of-Phase 2 meeting with FDA in Q4 2025

Topline results from RECLAIM trial in AUD expected in 2026

Result Drivers

Research and development expenses were $15.0 million for the three months ended September 30, 2025, compared to $19.8 million in the same period in 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$5,000
$600 (8 Analysts)
Q3 EPS
Beat
-$0.21
-$0.27 (9 Analysts)
Q3 Net Income
Beat
-$19.01 mln
-$23.60 mln (8 Analysts)
Q3 Income from Operations
Beat
-$20.86 mln
-$25.50 mln (8 Analysts)
Q3 Basic EPS
-$0.21
Q3 Operating Expenses
$20.86 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Altimmune Inc is $18.00, about 79.2% above its November 5 closing price of $3.75

Press Release: ID:nGNX21Cg96

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)